| Rogelio Magdiel Cantu, CRNA | |
|
301 W Expy 83, Mcallen, TX 78503-3045 | |
| (956) 632-4000 | |
| Not Available |
| Full Name | Rogelio Magdiel Cantu |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 11 Years |
| Location | 301 W Expy 83, Mcallen, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063836088 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 607412 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Laredo Medical Center | Laredo, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hospitalist Medicine Physicians Of Texas - Dallas Pllc | 3678966819 | 19 |
News Archive
In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.
› Verified 5 days ago
| Entity Name | Rio Grande Anesthesia & Pain Medicine Consultants, P .a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962457234 PECOS PAC ID: 4880507763 Enrollment ID: O20031106000738 |
News Archive
In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.
› Verified 5 days ago
| Entity Name | Northstar Anesthesia Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1912978610 PECOS PAC ID: 7315907128 Enrollment ID: O20041015000685 |
News Archive
In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.
› Verified 5 days ago
| Entity Name | Premier Anesthesia Of Huntsville A Division Of Premier Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346570355 PECOS PAC ID: 7012045685 Enrollment ID: O20100503000712 |
News Archive
In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.
› Verified 5 days ago
| Entity Name | Seven Flags Anesthesia Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1841625878 PECOS PAC ID: 5395971865 Enrollment ID: O20131112001248 |
News Archive
In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.
› Verified 5 days ago
| Entity Name | Texas Ams Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174926125 PECOS PAC ID: 9133441769 Enrollment ID: O20141209001912 |
News Archive
In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.
› Verified 5 days ago
| Entity Name | Hospitalist Medicine Physicians Of Texas - Dallas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164174124 PECOS PAC ID: 3678966819 Enrollment ID: O20220210000709 |
News Archive
In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Rogelio Magdiel Cantu, CRNA 2000 E Lamar Blvd, Suite 400, Arlington, TX 76006-7346 Ph: (817) 861-3994 | Rogelio Magdiel Cantu, CRNA 301 W Expy 83, Mcallen, TX 78503-3045 Ph: (956) 632-4000 |
News Archive
In the PLoS "Speaking of Medicine" blog, Leena Menghaney, a lawyer and India manager of the Access Campaign at Medecins Sans Frontieres, writes about "two critical legal battles between multinational pharmaceutical companies and the Indian government that are taking center stage in an ongoing struggle over India's medicines patent law."
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today initial 12-month clinical data from its ongoing Phase 2 open-label extension (OLE) study with patisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis) in patients with familial amyloidotic polyneuropathy (FAP).
Accelrys, Inc., a leading scientific enterprise R&D software and services company, today announced the signing of a partnership agreement with Oxford Nanopore Technologies Ltd. Under the terms of the partnership, Accelrys and Oxford Nanopore will develop software to enable complex, real-time analyses of experimental data produced by the Oxford Nanopore single molecule analysis system.
Valeant Pharmaceuticals International announced today that it has priced its previously announced private placement of $400 million of 7.625% senior unsecured notes due 2020. The principal amount was increased from the previously announced $350 million.
In a study of five diabetic patients with persistent macular edema, breathing supplemental oxygen for three months reduced fluid buildup and swelling in the macula and, in some cases, improved visual acuity. Researchers think the therapy could be used in conjunction with laser treatments that also improve oxygenation in the retina to provide long-term stability in these patients.
› Verified 5 days ago
Stacy Tavarez, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 301 W Expy 83, Mcallen, TX 78503 Phone: 956-632-4000 | |
Marla J Hadeler, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1305 E Nolana Ave, Ste H, Mcallen, TX 78504 Phone: 956-682-4151 Fax: 956-682-4154 | |
Nora J Coast, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 4228 N Mccoll Rd, Mcallen, TX 78504 Phone: 956-682-4151 Fax: 956-682-4154 | |
Jack Stout, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 222 E Ridge Rd, Suite 204, Mcallen, TX 78503 Phone: 956-632-6020 Fax: 956-630-6643 | |
Jorge Alvarez, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1309 E Ridge Rd Ste 3, Mcallen, TX 78503 Phone: 956-631-7202 Fax: 956-631-3026 | |
Stacy Marie Beach, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1809 S Cynthia St, Mcallen, TX 78503 Phone: 956-618-4402 Fax: 956-618-4174 |